Medherant Limited
Medherant develops drug delivery products for pain and CNS diseases using its proprietary TEPI Patch technology.
Medherant develops drug delivery products for pain and CNS diseases using its proprietary TEPI Patch technology.
Medherant is a clinical-stage pharmaceutical startup that specializes in developing innovative treatments for pain and CNS diseases. The company's flagship product is the TEPI Patch, a transdermal drug delivery technology based on a proprietary adhesive developed by its scientists. Founded in 2015 by Professor David Haddleton and the University of Warwick, Medherant's expertise lies in bioadhesives and polymer chemistry.
The TEPI Patch boasts a high drug loading capacity, allowing for a smaller quantity of adhesive to deliver a therapeutic dose, resulting in a thinner, more flexible patch. This proprietary technology also enables the inclusion of excipients in the adhesive, offering tailored drug release profiles. Additionally, the adhesive provides superior adhesion, even in moist conditions, ensuring the full dose is delivered without leakage or residue. Medherant also offers feasibility studies for companies interested in formulating drugs for transdermal delivery using the TEPI technology.
In its most recent funding round in 03 April 2023, Medherant secured a £2.90M investment from Mercia Asset Management. The company operates in the Pharmaceutical and Logistics and Delivery sectors, with its headquarters in the United Kingdom.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £2.90M | 1 | Mercia Asset Management | 03 Apr 2023 |
| Series A | €2.00M | 1 | Mercia Asset Management | 21 May 2019 |
| Grant | £52.00K | 1 |
|
03 Oct 2018 |
| Venture Round | £2.50M | 1 | Mercia Asset Management | 02 Jan 2018 |
| Seed Round | £1.50M | 1 | Mercia Asset Management | 26 Sep 2016 |
No recent news or press coverage available for Medherant Limited.
We care about your data, and we'd love to use cookies make your experience better.
